Stéphane Thomas

731 total citations
35 papers, 547 citations indexed

About

Stéphane Thomas is a scholar working on Epidemiology, Microbiology and Health. According to data from OpenAlex, Stéphane Thomas has authored 35 papers receiving a total of 547 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Epidemiology, 13 papers in Microbiology and 7 papers in Health. Recurrent topics in Stéphane Thomas's work include Bacterial Infections and Vaccines (13 papers), Pneumonia and Respiratory Infections (10 papers) and Hepatitis B Virus Studies (8 papers). Stéphane Thomas is often cited by papers focused on Bacterial Infections and Vaccines (13 papers), Pneumonia and Respiratory Infections (10 papers) and Hepatitis B Virus Studies (8 papers). Stéphane Thomas collaborates with scholars based in France, Italy and United States. Stéphane Thomas's co-authors include Anne Fiquet, Martine Baudin, Pierre Van Damme, Timo Vesikari, Alain Luxembourg, Giancarlo Icardi, Christine Sadorge, Javier Díez‐Domingo, Patrick O. Richard and Nicholas Brodszki and has published in prestigious journals such as Journal of Clinical Oncology, Vaccine and Archives of Disease in Childhood.

In The Last Decade

Stéphane Thomas

35 papers receiving 531 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stéphane Thomas France	13	442	128	99	98	80	35	547
Thorsten Rieck Germany	16	393 0.9×	66 0.5×	91 0.9×	133 1.4×	21 0.3×	28	488
Fabrice Bailleux France	14	628 1.4×	167 1.3×	195 2.0×	71 0.7×	139 1.7×	20	784
Naoko Nishimura Japan	16	388 0.9×	118 0.9×	299 3.0×	23 0.2×	61 0.8×	55	739
Anne Fiquet France	11	258 0.6×	88 0.7×	86 0.9×	62 0.6×	59 0.7×	22	357
Zsófia Mészner Hungary	13	275 0.6×	70 0.5×	143 1.4×	61 0.6×	23 0.3×	40	458
Heinz J. Schmitt Germany	9	417 0.9×	189 1.5×	107 1.1×	18 0.2×	56 0.7×	9	508
Monika Berney Switzerland	10	403 0.9×	52 0.4×	164 1.7×	48 0.5×	385 4.8×	14	842
James E. Froeschle United States	16	455 1.0×	384 3.0×	153 1.5×	52 0.5×	59 0.7×	26	672
Ricardo Rüttimann United States	14	362 0.8×	98 0.8×	360 3.6×	61 0.6×	36 0.5×	36	624
Christine Sadorge France	10	139 0.3×	75 0.6×	91 0.9×	20 0.2×	65 0.8×	15	356

Countries citing papers authored by Stéphane Thomas

Since Specialization

Citations

This map shows the geographic impact of Stéphane Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphane Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphane Thomas more than expected).

Fields of papers citing papers by Stéphane Thomas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphane Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphane Thomas. The network helps show where Stéphane Thomas may publish in the future.

Co-authorship network of co-authors of Stéphane Thomas

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphane Thomas. A scholar is included among the top collaborators of Stéphane Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphane Thomas. Stéphane Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sadorge, Christine, Matthew D. Snape, Richard Tomlinson, et al.. (2020). Randomized clinical trial of DTaP5-HB-IPV-Hib vaccine administered concomitantly with meningococcal serogroup C conjugate vaccines during the primary infant series. Vaccine. 38(35). 5718–5725. 1 indexed citations

Vesikari, Timo, et al.. (2018). Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers. Vaccine. 36(52). 8019–8027. 10 indexed citations

Zanetti, Alessandro, Maria Giuseppina Desole, Luisa Romanò, et al.. (2017). Safety and immune response to a challenge dose of hepatitis B vaccine in healthy children primed 10 years earlier with hexavalent vaccines in a 3, 5, 11-month schedule: An open-label, controlled, multicentre trial in Italy. Vaccine. 35(32). 4034–4040. 9 indexed citations

Martinón‐Torres, Federico, et al.. (2017). Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib). Vaccine. 35(30). 3764–3772. 10 indexed citations

Silfverdal, Sven‐Arne, Giancarlo Icardi, Timo Vesikari, et al.. (2016). A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11–12 months. Vaccine. 34(33). 3810–3816. 32 indexed citations

Vesikari, Timo, Thomas Becker, André Vertruyen, et al.. (2016). A Phase III Randomized, Double-blind, Clinical Trial of an Investigational Hexavalent Vaccine Given at Two, Three, Four and Twelve Months. The Pediatric Infectious Disease Journal. 36(2). 209–215. 22 indexed citations

Vesikari, Timo, Nicholas Brodszki, Pierre Van Damme, et al.. (2015). A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9–15-Year-Old Girls. The Pediatric Infectious Disease Journal. 34(9). 992–998. 79 indexed citations

Deichmann, Klaus A., et al.. (2015). Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad®) administered concomitantly with a booster dose of a hexavalent vaccine in 12–23-month-old infants. Vaccine. 33(20). 2379–2386. 11 indexed citations

Díez‐Domingo, Javier, Thomas Weinke, Juan García de Lomas, et al.. (2014). Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: A randomised non-inferiority clinical trial. Vaccine. 33(6). 789–795. 32 indexed citations

10.

Vesikari, Timo, et al.. (2013). Randomized, Controlled, Multicenter Study of the Immunogenicity and Safety of a Fully Liquid Combination Diphtheria–Tetanus Toxoid–Five-Component Acellular Pertussis (DTaP₅), Inactivated Poliovirus (IPV), and Haemophilus influenzae Type b (Hib) Vaccine Compared with a DTaP₃-IPV/Hib Vaccine Administered at 3, 5, and 12 Months of Age. Clinical and Vaccine Immunology. 20(10). 1647–1653. 8 indexed citations

11.

Gabutti, Giovanni, H. C. Rümke, Lars Rombo, et al.. (2012). Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine Manufactured With Recombinant Human Albumin. The Pediatric Infectious Disease Journal. 31(11). 1166–1172. 7 indexed citations

12.

Berner, Reinhard, et al.. (2012). Safety and immunogenicity of fully liquid DTaP5-IPV-Hib pediatric combination vaccine (Pediacel®) compared to DTaP3-HBV-IPV/Hib (Infanrix® Hexa) when coadministered with heptavalent pneumococcal conjugate vaccine (PCV7) as a booster at 11–18 months of age: A phase III, modified double-blind, randomized, controlled, multicenter study. Vaccine. 30(35). 5270–5277. 3 indexed citations

13.

Fiquet, Anne, et al.. (2011). Immunogenicity and safety of ZOSTAVAX® approaching expiry potency in individuals aged ≥50 years. Human Vaccines. 7(10). 1060–1065. 12 indexed citations

14.

Reinert, Philippe, Sandro Cinquetti, B. Soubeyrand, et al.. (2010). Challenge with hepatitis B vaccine in children previously vaccinated with a hepatitis B-containing combination vaccine. Advances in Therapy. 27(1). 28–38. 5 indexed citations

15.

Kitchin, Nicholas, Jo Southern, Rhonwen Morris, et al.. (2009). Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine. 27(37). 5096–5102. 14 indexed citations

16.

Gillet, Yves, et al.. (2009). Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro®) and a varicella vaccine (VARIVAX®) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial. BMC Medicine. 7(1). 16–16. 26 indexed citations

17.

Mair, Stuart, et al.. (2009). Immunogenicity and safety of PNEUMOVAX^®II manufactured by a new process in older adults. Human Vaccines. 5(9). 608–613. 3 indexed citations

18.

Walsh, Alissa, Satish Keshav, Otto C. Buchel, et al.. (2009). How variable is the mayo score between obnservers and might this affect trial recruitment or outcome. Journal of Gastroenterology and Hepatology. 24. 1 indexed citations

19.

Vesikari, Timo, Aino Karvonen, Nicholas Kitchin, et al.. (2008). CO-ADMINISTRATION OF PENTAVALENT ROTAVIRUS VACCINE, ROTATEQ®, WITH MENINGOCOCCAL GROUP C CONJUGATE VACCINE: IMMUNOGENICITY AND SAFETY. Archives of Disease in Childhood. 93. 1 indexed citations

20.

Díez‐Domingo, Javier, Francisco Sánchez, Antonio G. Cabrera, et al.. (2005). Immunogenicity and Reactogenicity of a Combined Adsorbed Tetanus Toxoid, Low Dose Diphtheria Toxoid, Five Component Acellular Pertussis and Inactivated Polio Vaccine in Six-Year-Old Children. The Pediatric Infectious Disease Journal. 24(3). 219–224. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact